Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...
ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback